A potent synthetic hexapeptide GH secretagogue with strong pituitary stimulation and moderate cortisol and prolactin co-secretion.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →GHRP-2 (Growth Hormone Releasing Peptide 2) is a second-generation synthetic GH secretagogue that represents a significant iterative refinement over the original GHRPs developed in the 1980s. Its full chemical name is D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2, and like its predecessor GHRP-6, it is a hexapeptide that acts as a potent agonist at the GHS-R1a (ghrelin receptor). Where GHRP-6 established that a synthetic peptide could robustly stimulate endogenous GH secretion, GHRP-2 improved upon this foundation in a specific and important way: it produces the strongest GH output of any commonly researched GHRP while moderating — though not eliminating — the appetite stimulation that characterized GHRP-6.
The structural differences between GHRP-2 and GHRP-6, while subtle at the amino acid level, translate into meaningful pharmacological distinctions. The substitution of D-beta-naphthylalanine (a bulky, aromatic unnatural amino acid) at position 2 in GHRP-2 compared to D-tryptophan in GHRP-6 alters the binding geometry of the peptide at GHS-R1a in ways that favor higher affinity and more efficient receptor coupling. This is reflected in the consistently higher GH peaks observed with GHRP-2 compared to GHRP-6 at equivalent doses across multiple comparative studies — often 30–50% higher peak GH concentrations. The same structural change appears to shift the balance of downstream receptor signaling in ways that produce less activation of the hypothalamic orexigenic circuits responsible for GHRP-6’s strong appetite drive.
GHRP-2 exists in the practical middle ground of the GHRP family. GHRP-6 produces maximum appetite stimulation with meaningful GH release and moderate cortisol/prolactin elevation. Ipamorelin, at the other end, produces minimal appetite stimulation and minimal cortisol/prolactin effects at the cost of lower GH output. GHRP-2 sits between these poles — highest GH output, moderate appetite stimulation (present but less overwhelming than GHRP-6), and moderate cortisol and prolactin elevation. This profile makes it arguably the most versatile of the commonly researched GHRPs for general GH axis restoration and body composition research, when the maximum GH pulse possible is a priority and some cortisol/prolactin elevation is acceptable.
GHRP-2 has been studied in research contexts ranging from GH deficiency treatment to body composition in athletes, from appetite modulation in cachexia to potential cardiac protection. The compound has a robust safety profile in published research and remains one of the most commonly referenced GHRPs in the contemporary peptide literature. Its synergy with GHRH analogs is particularly well-characterized, making GHRP-2 plus CJC-1295 one of the most frequently cited GHS combinations in research protocols. Detailed comparisons between GHRP-2 and related compounds are available in the Peptide Database.
GHRP-2 binds GHS-R1a with high affinity — higher than GHRP-6 in most binding studies — and initiates the same fundamental Gq/11-mediated signaling cascade as other GHRPs. GHS-R1a is constitutively active to approximately 50% of its maximum even without ligand bound, reflecting its tonic role in regulating GH pulsatility. When GHRP-2 binds, it pushes receptor activity toward its full agonist maximum, inducing conformational changes in the Gq/11 coupling domain that activate phospholipase C beta (PLCβ) with high efficiency. PLCβ cleaves membrane-bound phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) — the two second messengers that execute the downstream response.
IP3 diffuses to the endoplasmic reticulum and binds IP3 receptors (IP3R), triggering rapid release of stored calcium into the cytoplasm. In pituitary somatotroph cells, this calcium spike directly triggers fusion of GH-containing secretory vesicles with the plasma membrane, releasing GH into the portal blood. The efficiency of IP3-mediated calcium mobilization with GHRP-2 is greater than with GHRP-6, which directly accounts for the higher GH peaks observed with GHRP-2 — more calcium mobilized per receptor occupied translates to more vesicle fusion events per cell per injection. DAG, the parallel product of PIP2 hydrolysis, activates protein kinase C (PKC), which phosphorylates additional regulatory proteins that sustain and amplify the secretory response.
Protein kinase C (PKC) activation downstream of DAG production represents an important amplification layer in GHRP-2’s mechanism that distinguishes the kinetics of GHS-R1a-mediated GH release from the GHRH-mediated pathway. PKC has multiple downstream targets in somatotroph cells: it phosphorylates voltage-gated calcium channels (particularly L-type channels), increasing calcium entry from the extracellular space in addition to the IP3-triggered release from intracellular stores. This calcium entry provides a sustained calcium elevation that extends the window of GH vesicle exocytosis beyond the initial IP3-triggered spike. PKC also phosphorylates components of the secretory machinery itself, including SNAP-25 and synaptotagmin, increasing the efficiency of vesicle-membrane fusion.
The combination of IP3-triggered intracellular calcium release (fast, transient spike) and PKC-amplified calcium channel opening (slower, sustained elevation) creates a biphasic calcium signal that results in a larger and longer GH release event than either signal alone would produce. This biphasic calcium dynamics is a key mechanistic reason why GHRP-2 produces higher GH peaks than GHRH alone, even though GHRH’s cAMP/PKA pathway is capable of robust GH stimulation. When GHRP-2 and GHRH are combined, the PKA pathway from GHRH and the PKC pathway from GHRP-2 converge on the same secretory machinery through complementary phosphorylation events, producing the dramatic synergistic GH release that makes this combination one of the most effective GH stimulation strategies available to researchers.
The mechanistic basis for GHRP-2’s lesser orexigenic effect compared to GHRP-6 has been investigated but is not completely resolved. Several contributing factors have been proposed. First, the binding geometry of GHRP-2 at GHS-R1a — altered by the D-beta-naphthylalanine substitution — may favor functional selectivity: the receptor can adopt slightly different conformations depending on which ligand is bound, activating some downstream signaling pathways more than others even though the same receptor is engaged. This phenomenon, called biased agonism or functional selectivity, could explain how GHRP-2 and GHRP-6 both fully activate GHS-R1a yet produce different orexigenic outcomes.
Second, there appear to be regional differences in how efficiently GHRP-2 versus GHRP-6 penetrate specific brain regions. The arcuate nucleus of the hypothalamus, where NPY/AgRP orexigenic neurons are concentrated, may be accessed differently by the two compounds. Third, some research has suggested that GHRP-6 has additional interactions with receptors beyond GHS-R1a that contribute to its orexigenic effects — interactions that GHRP-2’s different structure may not replicate. The practical consequence is that users of GHRP-2 report hunger stimulation that is present and noticeable but manageable, rather than the overwhelming drive to eat that characterizes GHRP-6. This makes GHRP-2 better suited to research protocols where precise caloric control is needed alongside GH optimization.
The most directly relevant comparative finding in GHRP-2 research is its superior GH release potency versus other GHRPs. Multiple studies using standardized dose comparisons (typically 1–2 mcg/kg IV or 100–200 mcg SC in human subjects) have demonstrated that GHRP-2 produces GH peaks 30–50% higher than equivalent doses of GHRP-6 and substantially higher than ipamorelin. In one representative comparative study, the mean GH peak after GHRP-2 was approximately 25–30 mIU/L compared to 15–20 mIU/L with GHRP-6 and 8–12 mIU/L with ipamorelin — using the same dose per kilogram across all three compounds.
This potency advantage is consistent across populations: young adults, elderly subjects, GH-deficient patients, and obese individuals all show relatively larger GH responses to GHRP-2 than to GHRP-6 or ipamorelin. In GH deficiency diagnostic testing, GHRP-2 combined with GHRH has been proposed as a more sensitive stimulation test than arginine/GHRH or insulin tolerance testing, which are the traditional gold standards. A positive GHRP-2+GHRH test (adequate GH stimulation) effectively rules out pituitary GH deficiency, while a blunted response suggests impaired somatotroph reserve. This diagnostic utility has been particularly explored in pediatric patients for whom insulin tolerance testing carries unacceptable hypoglycemia risk.
The impact of GHRP-2 on body composition reflects the downstream consequences of sustained GH and IGF-1 elevation. GH promotes lipolysis in adipose tissue through hormone-sensitive lipase activation and reduces lipoprotein lipase activity in fat cells, shifting the balance toward fat mobilization rather than fat storage. IGF-1 — produced in the liver and locally in muscle in response to GH — drives protein synthesis and satellite cell activation in skeletal muscle, contributing to preservation and growth of lean tissue. In research protocols lasting 8–24 weeks with GHRP-2, these effects translate into measurable changes: reductions in total and visceral fat mass of 3–8%, increases in lean body mass of 1–3 kg, and improvements in body weight-normalized strength metrics.
These effects are modulated by several context variables: dietary protein and caloric intake, concurrent training stimulus, baseline body composition, and age (GH response tends to be smaller in obese individuals due to elevated circulating free fatty acids and somatostatin tone). When GHRP-2 is combined with a GHRH analog (which is the dominant approach in contemporary research), the body composition effects are amplified proportional to the larger GH response. Studies combining GHRP-2 with CJC-1295 have shown more robust lean mass accretion and fat mobilization than GHRP-2 alone, consistent with the mechanistically expected synergy.
The combination of GHRP-2 with GHRH analogs represents one of the best-characterized GH optimization strategies in peptide research. The mechanistic basis for synergy — complementary IP3/calcium (GHRP-2) and cAMP/PKA (GHRH) signaling pathways converging on the same secretory machinery — produces GH responses that are not just additive but multiplicative. In the seminal human pharmacology studies, the combination of GHRP-2 (100 mcg) with GHRH (100 mcg) produced GH peaks 4–6 times larger than either compound alone at equivalent doses. This degree of synergy is remarkably consistent and has been replicated using various GHRH analogs including native GHRH(1-44), Mod-GRF 1-29, and the long-acting CJC-1295 DAC formulation.
CJC-1295 with DAC (drug affinity complex) has a long half-life of 7–10 days due to albumin-binding technology, making it particularly convenient for research protocols — a single weekly or biweekly CJC-1295 injection combined with daily GHRP-2 injections maintains both elevated baseline GHRH signaling and acute GH pulses. Mod-GRF 1-29 (also called CJC-1295 without DAC) has a shorter half-life of 30 minutes and is used as a co-injection with GHRP-2, producing an acute synergistic GH pulse. The choice between the two GHRH analogs depends on whether sustained GH elevation or acute pulsatile stimulation is the research priority. Both achieve excellent synergy with GHRP-2, and the combination is widely considered the standard for GH optimization research.
GHRP-2 elevates both cortisol and prolactin — this is an intrinsic property of GHS-R1a agonism in the adrenal/ACTH and lactotroph compartments, shared across GHRPs. What distinguishes GHRP-2 from GHRP-6 in this regard is complex and somewhat counterintuitive: some comparative studies have found that GHRP-2 produces equal or slightly greater cortisol and prolactin elevation than GHRP-6 at doses producing equivalent GH stimulation. This might seem surprising given GHRP-2’s reputation as a more refined compound, but the mechanism makes sense: GHRP-2’s higher GHS-R1a affinity and more efficient receptor coupling that drives greater GH release also drives greater stimulation of corticotroph and lactotroph cells through the same receptor.
The absolute cortisol increase with GHRP-2 at standard research doses (100–200 mcg) is typically a 30–80% elevation above baseline, normalizing within 1–2 hours. Prolactin elevations follow a similar time course and magnitude. These are not clinically alarming values in acute use, but extended multi-daily dosing protocols that maintain elevated cortisol and prolactin throughout the day could have cumulative hormonal consequences. This is precisely why ipamorelin — which was specifically engineered to minimize these steroidogenic effects — has become preferred for users who want GH benefits without the cortisol/prolactin complication, even at the cost of lower GH output. GHRP-2’s cortisol profile positions it as appropriate for research contexts where maximum GH is the priority and steroidogenic effects are acceptable and monitored.
The age-related decline in GH secretion — sometimes called somatopause — is one of the most consistent and well-documented endocrine changes of aging. GH secretory output begins declining in the third decade of life and continues throughout adulthood, reaching levels in elderly individuals (over 70) that are 3–5 fold lower than young adult values. This decline contributes to the progressive changes in body composition (increasing adiposity, decreasing lean mass), bone mineral density, skin thickness, immune function, and exercise capacity that characterize aging. GHRP-2 has been specifically studied as a potential intervention for this age-related GH decline.
In elderly subjects, GHRP-2 produces GH peaks that are smaller than in young adults but still significantly elevated above the blunted baseline that characterizes somatopause. Long-term studies using GHRP-2 in elderly subjects have demonstrated progressive improvements in IGF-1, improvements in lean-to-fat mass ratios, and in some studies improvements in physical performance measures including grip strength and exercise tolerance. The question of whether these GH-restoring effects produce meaningful quality-of-life improvements or affect longevity-related biomarkers in elderly humans parallels similar questions about GH replacement therapy — an area of active research without yet definitive long-term outcome data.
GHRP-2 is administered subcutaneously in research contexts. The standard research dose is 100–300 micrograms per administration, with 100–200 mcg being the most common range for twice-daily protocols and 200–300 mcg used in protocols prioritizing maximal GH output. As with other GHRPs, GHRP-2 demonstrates a ceiling effect — GHS-R1a becomes saturated around 100–200 mcg, meaning doses above this range produce diminishing incremental GH increases while continuing to increase cortisol, prolactin, and appetite stimulation. For these reasons, the research consensus generally supports 100–200 mcg per injection as the practical effective range rather than escalating to higher doses. The Peptide Dosage Calculators provide tools for precise reconstitution and injection volume calculation.
The principles governing timing for GHRP-2 are the same as for other GHRPs: administration in a fasted state significantly improves GH response by minimizing insulin-driven somatostatin activation. Blood glucose and circulating free fatty acids both suppress the GH response to GHS stimulation, which is why post-meal injection produces consistently blunted GH peaks compared to fasted injection. A minimum of 2 hours post-meal (especially post-carbohydrate) is recommended. The pre-sleep window is pharmacologically ideal — combining GHRP-2 with the natural nighttime GH surge produces the highest total GH exposure. Morning fasted injection is the second most common timing choice. For protocols using two daily doses, the most common combination is pre-sleep plus morning fasted injection, separated by at least 3–4 hours to avoid partial receptor desensitization.
The most commonly used GHRP-2 protocol in contemporary research involves combining it with a GHRH analog, most often CJC-1295 (either with or without DAC). When using CJC-1295 without DAC (Mod-GRF 1-29, half-life ~30 minutes), both compounds are drawn into the same syringe and injected simultaneously — allowing the brief window of Mod-GRF 1-29 activity to overlap exactly with GHRP-2’s receptor-driven GH pulse. Standard dosing in these co-injection protocols uses 100 mcg of each compound per injection, typically twice daily (pre-sleep and morning fasted). When using CJC-1295 with DAC (longer-acting, 7–10 day half-life), GHRP-2 is injected separately on its own schedule (once or twice daily) while CJC-1295 DAC is injected once or twice per week to maintain a sustained GHRH background signal. This split-frequency approach is convenient but sacrifices the precise peak-timing synergy of co-injection with shorter-acting GHRH analogs.
Research protocols using GHRP-2 typically run for 8–16 weeks before a reassessment period. Continuous indefinite use is not well-studied and raises questions about long-term GHS-R1a regulation and sustained hormonal effects. Periodic assessment of serum IGF-1, fasting glucose, cortisol, and prolactin provides useful safety monitoring data and confirms that the desired GH axis response is being achieved. IGF-1 is the most practical marker of cumulative GH exposure since it reflects integrated GH activity over weeks rather than the momentary peaks measured by GH-stimulation tests. Target IGF-1 levels in research contexts are typically within the mid-to-upper range of age-normalized reference values — supraphysiological IGF-1 elevation is not a stated goal of responsible GHS research. The AI Peptide Coach can help frame GHRP-2 within structured research protocols with appropriate monitoring checkpoints.
The most consequential safety consideration specific to GHRP-2 is its reliable elevation of both cortisol and prolactin with each administration. In the context of twice-daily dosing over weeks to months, the cumulative hormonal environment created by repeated transient cortisol and prolactin spikes deserves careful consideration. Chronically elevated cortisol — even transiently elevated multiple times per day — can contribute over time to insulin resistance, reduced testosterone production (cortisol is catabolic and suppresses Leydig cell function), impaired immune function, and psychological effects including anxiety and mood dysregulation. These concerns apply particularly in protocols using high doses or more than twice-daily administration. Baseline cortisol measurement (morning serum cortisol) and periodic follow-up cortisol assessment allow detection of any cumulative hypercortisolism. Using lower effective doses (100 mcg rather than 300 mcg per injection) minimizes cortisol elevation while preserving most of the GH-stimulatory benefit.
Elevated GH levels — whether from exogenous rhGH or from secretagogue-stimulated endogenous GH — produce a predictable set of physiological responses that can manifest as side effects. Sodium and water retention cause edema (swelling) in the extremities and face, particularly during the first 2–4 weeks of a new GHS protocol before the body adapts. Increased carpal tunnel pressure from this fluid retention can cause numbness, tingling, or pain in the hands and fingers — a dose-dependent effect that typically resolves with dose reduction. In healthy adults without pre-existing nerve compression, these effects are reversible. Joint pain (arthralgia) is another GH-associated effect reflecting changes in connective tissue hydration and metabolism. Titrating upward slowly from a lower starting dose and managing sodium intake helps attenuate these effects. They should not be ignored, as they provide feedback about whether the GH response to the protocol is appropriate to individual tolerance.
GHRP-2’s moderate orexigenic effect is less severe than GHRP-6’s but still present and should be planned around in research protocols. The interaction between GH’s diabetogenic properties (GH is an insulin counter-regulatory hormone) and GHRP-2’s orexigenic effects on total caloric intake creates a potential metabolic complication in individuals predisposed to insulin resistance. GH promotes hepatic glucose output and reduces peripheral glucose uptake, which transiently raises blood glucose post-administration. In healthy individuals with normal insulin sensitivity, the pancreatic beta cell compensates adequately. In individuals with pre-diabetes, metabolic syndrome, or impaired glucose tolerance, GHRP-2 protocols warrant fasting glucose and HbA1c monitoring. The appetite stimulation adds a separate caloric surplus risk that could further worsen metabolic parameters if dietary intake is not managed. For these reasons, individuals with known insulin resistance should approach GHRP-2 protocols conservatively and with appropriate medical oversight.
The most practically significant differences are GH output (GHRP-2 higher) and appetite stimulation (GHRP-2 lower). If you are a researcher who wants maximum GH stimulation and is willing to manage the hunger drive carefully, GHRP-2 provides more GH per injection. If the pronounced hunger from GHRP-6 is not a problem for your research context — for example, in a cachexia or mass gain study — then GHRP-6’s stronger appetite stimulation might actually be advantageous. For most body composition optimization research in healthy adults where both GH maximization and manageable side effects are important, GHRP-2 is the more frequently chosen option. The cortisol and prolactin profiles are similar between the two, with GHRP-2 possibly producing slightly more steroidogenic stimulation at doses producing equivalent GH peaks.
“Better” depends entirely on the research goal. Ipamorelin’s advantage — minimal cortisol, minimal prolactin, minimal appetite stimulation — comes at the cost of significantly lower GH output. In a context where the research priority is clean GH stimulation without any hormonal “noise,” ipamorelin is superior. In a context where maximum GH release is the objective and cortisol/prolactin elevation is an acceptable and monitored trade-off, GHRP-2 outperforms ipamorelin substantially. A practical heuristic used in research settings: if IGF-1 optimization in healthy adults is the goal and side effect minimization matters, use ipamorelin. If GH output maximization for body composition or recovery acceleration is the priority, use GHRP-2. The Peptide Database has a detailed side-by-side comparison of the entire GHRP class.
Yes, and this is one of the more compelling potential applications. Age-related GH decline (somatopause) is characterized primarily by increased hypothalamic somatostatin tone and reduced GHRH pulsatility — with the pituitary somatotroph cells themselves retaining substantial GH secretory capacity. Since GHRP-2 acts directly on pituitary GHS-R1a and also reduces somatostatin tone at the hypothalamic level, it can effectively stimulate GH release even when endogenous regulation has become blunted. Research in elderly subjects has demonstrated meaningful GH pulse restoration with GHRP-2. When combined with a GHRH analog, the synergistic response is particularly valuable in older individuals because it addresses both the somatostatin excess and the reduced GHRH drive simultaneously. Expected GH peaks will still be lower than in young adults, but the relative improvement from a blunted baseline is substantial.
The mechanistic rationale is solid. GH and IGF-1 are well-established promoters of collagen synthesis, bone remodeling, muscle protein synthesis, and connective tissue repair. Elevating these through GHRP-2 stimulation during the recovery phase of an injury could theoretically accelerate healing of muscle, tendon, ligament, and bone injuries. Some research has specifically examined GHS compounds (including ghrelin and GHS analogs) in bone fracture healing and wound repair models, showing accelerated healing. In practice, GHRP-2 is used in sports medicine research contexts precisely because it stimulates the body’s own GH pulse rather than introducing exogenous GH — maintaining the pulsatile pattern believed to be important for optimal tissue remodeling. Combining GHRP-2 with peptides specifically addressing local tissue repair mechanisms (such as BPC-157 for soft tissue) represents an approach where the systemic (GH axis) and local (tissue-specific) mechanisms are addressed simultaneously.
GH secretion is physiologically concentrated in the early phases of slow-wave sleep, and the GH pulse that occurs approximately 90 minutes after sleep onset is the single largest GH pulse of the 24-hour day in young adults. GHRPs administered pre-sleep amplify this natural nighttime GH pulse by adding GHS-R1a stimulation to the already favorable hormonal environment of early sleep. Research subjects using GHRPs before sleep typically report subjectively deeper sleep and improved morning recovery — effects consistent with enhanced slow-wave sleep quality. Some EEG studies have documented increased slow-wave sleep duration with GH secretagogue administration before sleep. This sleep-quality improvement likely reflects a combination of the larger GH pulse, GHS-R1a’s own sleep-regulatory role in the hypothalamus, and the downstream neuro-restorative effects of GH during sleep. Pre-sleep dosing with GHRP-2 (combined with Mod-GRF 1-29 for synergy) is the administration context most likely to produce sleep-related benefits.
Standard research practice involves cycles of 8–16 weeks followed by an off period of 4–8 weeks. The rationale for cycling includes preventing receptor desensitization (though this is less of a concern with twice-daily dosing than with more frequent administration), allowing cortisol and prolactin levels to normalize, and providing time to assess whether the protocol objectives (IGF-1 elevation, body composition changes) have been achieved before continuing. Some research frameworks use continuous GHRP-2 protocols for 6 months with quarterly biomarker assessment rather than strict on-off cycling, particularly in the context of GH deficiency or age-related somatopause research. The most important cycling principle is probably not the specific on/off duration but rather maintaining appropriate laboratory monitoring throughout and adjusting protocol parameters based on biomarker feedback. Consult the AI Peptide Coach for structured cycle planning guidance.
GHRP-2 has been studied in female subjects and works through the same mechanisms. Women have naturally higher baseline GH pulsatility than men due to estrogen’s augmentation of GH secretion, which means baseline GH is higher but incremental responses to GHRPs can be relatively smaller compared to baseline. The prolactin-elevating effect of GHRP-2 has particular relevance in women — elevated prolactin can disrupt the menstrual cycle, suppress LH and FSH, and affect fertility. For women of reproductive age using GHRP-2 in research, prolactin monitoring is especially important. Post-menopausal women have different hormonal dynamics and may respond differently to GHRP-2’s interactions with the reproductive axis. Standard research precautions apply across sexes: careful dose titration, periodic biomarker monitoring, and avoidance during pregnancy.
GH is a well-established insulin antagonist — it increases hepatic glucose output, reduces muscle glucose uptake, and promotes free fatty acid mobilization from adipose tissue, all of which work against insulin action. Chronic GH elevation in acromegaly causes frank type 2 diabetes in many patients. With GHRPs producing more modest, pulsatile GH elevation rather than continuous supraphysiological GH, the insulin-antagonizing effects are less severe but not absent. Short-term GHRP-2 research shows transient rises in fasting glucose and insulin levels, particularly in the hours after injection when GH levels are highest. With longer-term use in individuals with normal metabolic baseline, glucose and insulin usually normalize between pulses. However, in metabolically compromised individuals, the cumulative GH-mediated insulin resistance from repeated daily pulses can contribute meaningfully to worsening glycemic control. This is one of the strongest arguments for careful metabolic monitoring (fasting glucose, fasting insulin, HbA1c) in extended GHRP-2 research protocols.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.